A company that counts several prominent hedge funds from the Tiger Management crowd among its major investors has filed plans to go public.
But it is not a unicorn or an internet, technology, or new media company.
Rather, it is the latest among a growing number of fledgling biopharma companies looking to raise money in the public markets.